BTG plc (LON:BTG)‘s stock had its “buy” rating reaffirmed by research analysts at Deutsche Bank AG in a research report issued to clients and investors on Friday.

Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. lifted their price target on BTG plc from GBX 790 ($10.31) to GBX 830 ($10.83) and gave the stock a “neutral” rating in a research report on Friday. Stifel Nicolaus reaffirmed a “hold” rating and set a GBX 640 ($8.35) price target on shares of BTG plc in a research report on Thursday. Numis Securities Ltd reissued a “hold” rating and issued a GBX 737 ($9.62) target price on shares of BTG plc in a report on Thursday. Finally, Jefferies Group reissued a “buy” rating and issued a GBX 860 ($11.23) target price on shares of BTG plc in a report on Friday, July 15th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of GBX 799.57 ($10.44).

Analyst Recommendations for BTG plc (LON:BTG)

Shares of BTG plc (LON:BTG) traded up 2.56% on Friday, reaching GBX 701.50. The company’s stock had a trading volume of 980,141 shares. The company has a 50 day moving average of GBX 629.82 and a 200 day moving average of GBX 641.22. The stock’s market capitalization is GBX 2.69 billion. BTG plc has a 1-year low of GBX 504.00 and a 1-year high of GBX 739.50.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

In related news, insider Soderstrom,Rolf sold 74,327 shares of the company’s stock in a transaction on Thursday, July 21st. The stock was sold at an average price of GBX 676 ($8.82), for a total transaction of £502,450.52 ($655,855.01).

BTG plc Company Profile

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with's FREE daily email newsletter.